Vice President, Portfolio Sales and Field Team
Revolution Medicines
Summary
The Vice President, Oncology Sales will lead the design, build, and execution of a high-performing, national oncology sales organization supporting Revolution Medicines products/services to the oncology community. Reporting to the SVP of US Marketing & Field, the VP will be responsible for creating and scaling a best-in-class sales organization, ensuring successful product launches, and driving sustained revenue growth.
Job description
Key Responsibilities
Organizational Build & Leadership
- Architect and execute the build-out of a national portfolio oncology sales organization, including hiring, onboarding, and development of regional leaders, account directors, and sales representatives.
- Establish organizational structure, roles, and deployment strategy aligned to brand objectives and market dynamics.
- Foster a high-performance culture grounded in accountability, collaboration, innovation, and patient-centricity.
- Develop leadership bench strength through coaching, succession planning, and talent development initiatives.
Strategic & Commercial Leadership
- Define and execute the national sales strategy across oncology indications, ensuring alignment with corporate objectives and brand strategies.
- Lead all aspects of product launch readiness and execution, including field deployment, targeting, messaging alignment, and performance tracking.
- Partner with Commercial Leadership Team to shape enterprise-wide strategy, providing field insights and actionable recommendations.
- Drive achievement of all revenue and performance targets, ensuring consistent delivery against quarterly and annual goals.
Sales Operations & Execution Excellence
- Oversee development and execution of key commercial levers including: Forecasting and demand planning, Incentive compensation design, Territory alignment and targeting, Performance analytics and reporting, Training and capability development programs.
- Ensure disciplined execution of business plans and continuous optimization based on market feedback and data insights.
Key Account & Market Engagement
- Lead strategy and executive engagement for top national accounts, including major health systems, IDNs, oncology networks, and GPOs.
- Oversee development and execution of strategic account plans that drive access, adoption, and long-term partnerships.
- Serve as a senior external representative of the company with key stakeholders and decision-makers.
Cross-Functional Collaboration
- Partner closely with Marketing, Market Access, Medical Affairs, Commercial Operations, and Training to ensure aligned execution.
- Lead cross-functional initiatives to address business challenges, optimize launch performance, and enhance customer experience.
- Act as the “voice of the field” to inform brand strategy, pipeline planning, and organizational priorities.
- Shape clinical development planning and prioritization.
Compliance & Governance
- Ensure all field activities adhere to regulatory, legal, and compliance standards.
- Model and reinforce ethical leadership and decision-making across the organization.
Required Skills, Experience and Education
- Bachelor’s degree required; advanced degree (MBA, PharmD, PhD) preferred.
- 25+ years of biopharmaceutical industry experience, including significant oncology leadership.
- Proven track record of building and scaling sales organizations, preferably in small-to-mid-size biotech environments.
- Demonstrated success leading oncology product launches, including oral oncolytics.
- Prior leadership of second-line leaders (e.g., regional directors managing managers and reps).
- Deep expertise in oncology market dynamics, including GI, NSCLC preferred.
- Strong strategic, analytical, and operational leadership capabilities.
- Experience working in highly cross-functional, matrixed organizations.
- Willingness to travel (~50%).
Preferred Skills
- Experience in NSCLC and/or GI oncology markets.
- Broad understanding of commercial functions including market access, marketing, training, and sales operations.
- Demonstrated ability to influence at executive levels internally and externally.
- Strong project management and organizational skills, with the ability to manage multiple priorities.
- Proven ability to build culture and lead through change in high-growth environments.
Requirements
- Bachelor’s degree required
- 25+ years of biopharmaceutical industry experience, including significant oncology leadership
- Proven track record of building and scaling sales organizations, preferably in small-to-mid-size biotech environments
- Demonstrated success leading oncology product launches, including oral oncolytics
- Prior leadership of second-line leaders (e.g., regional directors managing managers and reps)
- Deep expertise in oncology market dynamics, including GI, NSCLC preferred
- Strong strategic, analytical, and operational leadership capabilities
- Experience working in highly cross-functional, matrixed organizations
- Willingness to travel (~50%)
Benefits
- Equity Awards
- Health Benefits
- Learning And Development Opportunities
- Potential Bonus Or Commission
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.